Calliditas Therapeutics soars on FDA approval of kidney disease drug

Calliditas Therapeutics AB

20/12/2023 22:47

** ADRs of Swedish drugmaker Calliditas Therapeutics
 CALT.O  rise ~25% to $28.06 aftermarket 
    ** The drug branded as Tarpeyo will be used to treat rare
kidney disease IgA Nephropathy (IgAN), also known as Berger's
disease, which affects about 130,000–150,000 people in U.S.
    ** The FDA decision makes Tarpeyo first to be granted full
approval in U.S. for IgAN, ahead of Travere Therapeutics'
 TVTX.O  Filspari which won accelerated approval earlier this
year
    ** Roche  ROG.S , Novartis  NOVN.S , Vera Therapeutics
 VERA.O  are among peers working on a treatment for IgAN and are
currently in mid to late-stage development trials
    ** Up to day's close, stock had risen 32% YTD

 (Reporting by Aatreyee Dasgupta)
 ((Aatreyee.Dasgupta@thomsonreuters.com))